TAR-200: A New “Pretzel” Treatment for Bladder Cancer

TAR-200: A New “Pretzel” Treatment for Bladder Cancer

A new bladder cancer treatment called TAR-200 is giving hope to many patients with bladder cancer that has come back after treatment. Some doctors and patients call it the “pretzel treatment” because of its curly shape.

TAR-200 is a clinical trial designed for people with a type of bladder cancer called non-muscle invasive bladder cancer (NMIBC). This means the cancer is still inside the inner lining of the bladder and has not grown into the bladder muscle. 

What Is TAR-200?

TAR-200 is a first-in-class small soft device that is placed inside the bladder through a thin tube called a catheter. Once inside the bladder, it curls into a pretzel-like shape so it stays in place. 

The device slowly releases a chemotherapy medicine called gemcitabine directly into the bladder over several weeks. This allows the medicine to stay in contact with the cancer longer than standard bladder treatments. 

How Does TAR-200 Work?

TAR-200 works in a different way than regular chemotherapy.

Instead of giving medicine through a vein, TAR-200 puts the medicine right where the cancer is located inside the bladder.

The device slowly releases gemcitabine day and night. Doctors hope this steady treatment can:

• Kill cancer cells
• Lower the chance the cancer comes back
• Help patients avoid bladder removal surgery

Researchers say the treatment may also help the immune system fight the cancer. 

Who May Qualify for TAR-200?

TAR-200 is mainly being studied for patients who:

• Have high-risk non-muscle invasive bladder cancer
• Already received BCG treatment
• Had cancer come back after BCG
• Cannot have or do not want bladder removal surgery

Some studies are also looking at TAR-200 for other bladder cancer groups. 

What Are the Side Effects?

Most side effects are related to the bladder and urinary system.

Common side effects include:

• Frequent urination
• Burning or pain during urination
• Blood in the urine
• Urinary tract infections
• Bladder spasms or discomfort
• Feeling the need to urinate often

Many patients are still able to continue their normal daily activities during treatment. 

How Well Is TAR-200 Working?

Early study results have been very encouraging.

In one important clinical trial:

• More than 80% of patients had their cancer disappear after treatment
• Many patients stayed cancer-free for at least one year

Researchers called the results a major breakthrough for some bladder cancer patients.

Is TAR-200 Approved?

TAR-200 has been studied in several clinical trials and has shown strong results. Johnson & Johnson submitted the treatment to the U.S. FDA for review in 2025, and it was approved in September, 2025.

Some reports now refer to the treatment by the brand name Inlexzo. 

TAR -200 Clinical Trial With Cetrelimab

The SUNRISE-1 clinical trial is a Phase 2b clinical study evaluating the safety and efficacy of TAR-200, testing it with the drug cetrelimab.

Final Thoughts

TAR-200 is one of the most exciting new bladder cancer treatments in years. By slowly delivering chemotherapy directly into the bladder, it may help some patients avoid major surgery while still controlling the cancer.

If you are interested in TAR-200 should talk with your urologist or bladder cancer specialist to see whether this treatment or a clinical trial may be right for you.